Adults with type 1 diabetes and overweight or obesity prescribed tirzepatide off-label had a reduction in body weight and improvements in HbA1c and continuous glucose monitoring metrics, according to data from a real-world study.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045